Todd Foley, M.B.A.
Investment and Operations Team
Todd Foley, an experienced biotech investor, is a Managing Director at MPM Capital and serves on a number of MPM portfolio company boards, including Chiasma (NASDAQ: CHMA), CODA Biotherapeutics, Entrada Therapeutics, Iconic Therapeutics, Repare Therapeutics (NASDAQ: RPTX), Rhythm Pharmaceuticals (NASDAQ: RYTM), and Tetherex Pharmaceuticals. He previously served on the board of Semma Therapeutics, a potentially curative diabetes cell-therapy company founded by MPM and Doug Melton at Harvard, which was acquired by Vertex for $950M in 2019 in one of the largest ever preclinical M&A deals. He guided Selexys Pharmaceuticals to an acquisition by Novartis for $665M in 2016; Novartis launched the Selexys drug, Adakveo™ in late 2019 to treat sickle cell disease.
Todd has managed MPM’s strategic investment relationship with Novartis, which committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures.
Prior to joining MPM in 1999, Todd’s career in the life science industry included business development at Genentech (Roche) and management consulting with Arthur D. Little.
Todd earned his M.B.A. from Harvard Business School and his B.S. in Chemistry from the Massachusetts Institute of Technology.